SCHEMBL4865615

SCHEMBL4865615

Cc1ccccc1/C=C/C(=O)c1ccccc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.56
GUSB P08236 1/20 0.56
MAPT P10636 5/20 0.52
KDM4E B2RXH2 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
MEN1 O00255 3/20 0.52
POLB P06746 3/20 0.52
KMT2A Q03164 3/20 0.52
TDP1 Q9NUW8 3/20 0.52
LMNA P02545 3/20 0.52
HSP90AA1 P07900 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
ALOX12 P18054 2/20 0.52
HTT P42858 2/20 0.52
GPR52 Q9Y2T5 1/20 0.51
RAB9A P51151 2/20 0.51
MAOB P27338 3/20 0.50
AR P10275 1/20 0.50
NFE2L2 Q16236 1/20 0.49
CHRNA7 P36544 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28814893 0.88 BCHE (0.75) BCHEGUSBMAPTLMNAMAOB
SCHEMBL675698 0.88 BCHE (0.75) BCHEGUSBMAPTKDM4ESMN1; SMN2
SCHEMBL8101054 0.88 BCHE (0.75) BCHEGUSBMAPTKDM4ESMN1; SMN2
SCHEMBL23956015 0.86 LMNA (0.61) BCHEGUSBMAPTKDM4ESMN1; SMN2
SCHEMBL11528927 0.84 GPR52 (0.61) MAPTKDM4ESMN1; SMN2LMNAHTT
SCHEMBL11528932 0.84 GPR52 (0.61) MAPTKDM4ESMN1; SMN2LMNAHTT
SCHEMBL23830003 0.84 CHRNA7 (0.60) MAPTKDM4ESMN1; SMN2MEN1POLB
SCHEMBL15631497 0.84 ABCG2 (0.68) BCHEMAPTKDM4EMEN1POLB
SCHEMBL23830004 0.84 CHRNA7 (0.60) MAPTKDM4ESMN1; SMN2MEN1POLB
SCHEMBL25289436 0.81 NFE2L2 (0.71) BCHEGUSBMAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118894756-A Deoxidization and reduction method for alpha, beta unsaturated ketone 温州医科大学 2024-11-05 CN disclosed
WO-2023177194-A1 NOVEL DIMETHYLCHALCONE DERIVATIVES 중앙대학교 산학협력단 2023-09-21 WO disclosed
WO-2023177191-A1 COMPOSITION FOR PREVENTING OR TREATING FIBROTIC DISEASES, COMPRISING DIMETHYLCHALCONE DERIVATIVE AS ACTIVE INGREDIENT 서울대학교 산학협력단 2023-09-21 WO disclosed
US-20230248665-A1 COMPOSITION COMPRISING DIMETHYLCHALCONE DERIVATIVE FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) 2023-08-10 US disclosed
US-20230248665-A1 COMPOSITION COMPRISING DIMETHYLCHALCONE DERIVATIVE FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) 2023-08-10 US disclosed
WO-2022060169-A4 COMPOSITION COMPRISING DIMETHYLCHALCONE DERIVATIVE FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE 서울대학교 산학협력단 2022-05-12 WO disclosed
US-7432303-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states Bowen, J. Phillip (US) 2008-10-07 US disclosed
US-20050148599-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230248665-A1 COMPOSITION COMPRISING DIMETHYLCHALCONE DERIVATIVE FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE LIPC, PC, CYP27A1 BCHE 612/4885GUSB 2657/4885MAPT 1563/4885
US-20050148599-A1 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states FLT1, VEGFA, FLT4 BCHE 4276/4885GUSB 2239/4885MAPT 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.